tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AQST Stock Latest News

Aquestive Therapeutics Faces Potential Risks with ‘5050Item’: What Investors Need to Know
Company AnnouncementsAquestive Therapeutics Faces Potential Risks with ‘5050Item’: What Investors Need to Know
4d ago
AQST
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer
PremiumThe Fly
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer
14d ago
AQST
Aquestive Therapeutics provides international expansion update for Anaphylm
PremiumThe Fly
Aquestive Therapeutics provides international expansion update for Anaphylm
21d ago
AQST
Aquestive Therapeutics announces two presentations on Anaphylm
PremiumThe Fly
Aquestive Therapeutics announces two presentations on Anaphylm
1M ago
AQST
Positive Outlook for Aquestive Therapeutics Amidst FDA Progress and Strategic Preparations for Anaphylm Launch
PremiumRatings
Positive Outlook for Aquestive Therapeutics Amidst FDA Progress and Strategic Preparations for Anaphylm Launch
2M ago
AQST
Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Progress and Market Potential
PremiumRatingsBuy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Progress and Market Potential
2M ago
AQST
FDA Accepts Aquestive’s New Drug Application for Anaphylm
Premium
Company Announcements
FDA Accepts Aquestive’s New Drug Application for Anaphylm
2M ago
8K
AQST
Aquestive announces FDA acceptance of NDA, PDUFA date for Anaphylm
Premium
The Fly
Aquestive announces FDA acceptance of NDA, PDUFA date for Anaphylm
2M ago
AQST
Aquestive Therapeutics Holds Annual Stockholders Meeting
PremiumCompany Announcements
Aquestive Therapeutics Holds Annual Stockholders Meeting
2M ago
8K
AQST
Aquestive Therapeutics Prepares for FDA Approvals and Launches
PremiumCompany Announcements
Aquestive Therapeutics Prepares for FDA Approvals and Launches
2M ago
8K
AQST
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
PremiumThe Fly
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
2M ago
AQST
Aquestive Therapeutics price target lowered to $7 from $15 at Oppenheimer
PremiumThe Fly
Aquestive Therapeutics price target lowered to $7 from $15 at Oppenheimer
2M ago
AQST
Aquestive Therapeutics’ Earnings Call: Mixed Outlook
PremiumCompany AnnouncementsAquestive Therapeutics’ Earnings Call: Mixed Outlook
3M ago
AQST
Buy Recommendation for Aquestive Therapeutics: Promising Prospects for Anaphylm’s Market Launch and Growth
Premium
Ratings
Buy Recommendation for Aquestive Therapeutics: Promising Prospects for Anaphylm’s Market Launch and Growth
3M ago
AQST
Strategic Shift and Financial Positioning Drive Buy Rating for Aquestive Therapeutics Amid Anaphylm Launch Preparations
Premium
Ratings
Strategic Shift and Financial Positioning Drive Buy Rating for Aquestive Therapeutics Amid Anaphylm Launch Preparations
3M ago
AQST
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm
PremiumCompany Announcements
Aquestive Therapeutics’ Q1 2025: Focus on Anaphylm
3M ago
AQST
Aquestive Therapeutics price target lowered to $5 from $8 at Piper Sandler
PremiumThe Fly
Aquestive Therapeutics price target lowered to $5 from $8 at Piper Sandler
3M ago
AQST
Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c)
PremiumThe Fly
Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c)
3M ago
AQST
Aquestive Therapeutics Submits NDA for Anaphylm
PremiumCompany Announcements
Aquestive Therapeutics Submits NDA for Anaphylm
3M ago
8K
AQST
Aquestive Therapeutics, Inc. (AQST) Q1 Earnings Cheat Sheet
PremiumPre-EarningsAquestive Therapeutics, Inc. (AQST) Q1 Earnings Cheat Sheet
3M ago
AQST
Buy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
Premium
Ratings
Buy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
4M ago
AQST
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success
Premium
Ratings
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success
4M ago
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >